SUVEN — Suven Life Sciences Share Price
0.000.00%
Last trade - 00:00- IN₹29.07bn
- IN₹27.41bn
- IN₹116.93m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.51 | ||
| PEG Ratio (f) | 0.45 | ||
| EPS Growth (f) | 19.87% | ||
| Dividend Yield (f) | 1.1% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 15.39 | ||
| Price to Tang. Book | 15.41 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 391.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -81.55% | ||
| Return on Equity | -53.98% | ||
| Operating Margin | -2089.04% | ||
Financial Summary
| Year End 31st Mar | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | IN₹m | 144.15 | 134.78 | 118.44 | 135.39 | 116.93 | 11,736 | 14,834 | -47.23% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +19.87 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Suven Life Sciences Limited is an India-based biopharmaceutical company, which is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs, globally. The Company's lead clinical-stage assets include Masupirdine (Pure 5-HT 6 receptor antagonist), Samelisant (Histamine 3 receptor inverse agonist) and Ropanicant (a4b2 antagonist). Masupirdine is an ongoing phase III study for agitation and aggression in Alzheimer's type dementias in North America and Europe. Samelisant is a study on the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. Ropanicant is an ongoing screening for Phase II open label study for moderate to severe major depressive disorder in United States. Its other clinical-stage assets include Usmarapride (5-HT4 receptor agonist), SUVN-I6107 (True muscarinic M1 positive allosteric modulator) and SUVN-D1044 (5-HT4 receptor agonist).
Directors
- Venkateswarlu Jasti CHM (72)
- P. Subba Rao CFO
- Shrenik Soni CCO
- Sudha Jasti EDR (61)
- M. Gopalakrishna NID
- Syed Hasnain NID
- Santanu Mukherjee NID
- M. Naidu NID
- J.A.S Padmaja NID (56)
- D. Prasad NID
- Last Annual
- March 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 9th, 1989
- Public Since
- March 6th, 1995
- No. of Shareholders
- 68,959
- No. of Employees
- 141
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 218,074,000
- Address
- SDE Serene Chambers 6th Floor, HYDERABAD, 500034
- Web
- https://www.suven.com/
- Phone
- +91 4023541142
- Contact
- Shrenik Soni
- Auditors
- Karvy & Company
Upcoming Events for SUVEN
Suven Life Sciences Ltd Annual Shareholders Meeting
Q1 2026 Suven Life Sciences Ltd Earnings Release
Q2 2026 Suven Life Sciences Ltd Earnings Release
Similar to SUVEN
Biocon
National Stock Exchange of India
Indo US Bio-Tech
National Stock Exchange of India
Onesource Specialty Pharma
National Stock Exchange of India
Syngene International
National Stock Exchange of India
Take Solutions
National Stock Exchange of India
FAQ
What is the Suven Life Sciences share price?
As of Today at 23:30 UTC, shares in Suven Life Sciences are trading at IN₹135.99. This share price information is delayed by 15 minutes.
How has the Suven Life Sciences share price performed this year?
Shares in Suven Life Sciences last closed at IN₹135.99 and the price had moved by +19.71% over the past 365 days. In terms of relative price strength the Suven Life Sciences share price has outperformed the S&P BSE 100 Index by +12.77% over the past year.
What are the analyst and broker recommendations for Suven Life Sciences?
The overall consensus recommendation for Suven Life Sciences is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Suven Life Sciences dividend yield?
Suven Life Sciences does not currently pay a dividend.
Does Suven Life Sciences pay a dividend?
Suven Life Sciences does not currently pay a dividend.
When does Suven Life Sciences next pay dividends?
Suven Life Sciences does not currently pay a dividend.
How do I buy Suven Life Sciences shares?
To buy shares in Suven Life Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Suven Life Sciences?
As of the previous close price of IN₹135.99, shares in Suven Life Sciences had a market capitalisation of IN₹29.07bn.
Where are Suven Life Sciences shares listed?
Here are the trading details for Suven Life Sciences:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: SUVEN
What kind of share is Suven Life Sciences?
Based on an overall assessment of its quality, value and momentum Suven Life Sciences is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Suven Life Sciences share price forecast for 2025?
The analyst consensus target price for shares in Suven Life Sciences is IN₹287.64. That is 111.51% above the last closing price of IN₹135.99.
Analysts covering Suven Life Sciences currently have a consensus Earnings Per Share (EPS) forecast of IN₹15.10 for the next financial year.
Find out moreWhat is the trend in the Suven Life Sciences share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Suven Life Sciences. Over the past six months, its share price has outperformed the S&P BSE 100 Index by +21.97%.
As of the last closing price of IN₹135.99, shares in Suven Life Sciences were trading +3.09% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Suven Life Sciences PE Ratio?
The Suven Life Sciences PE ratio based on its reported earnings over the past 12 months is 7.51. The shares last closed at IN₹135.99.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Suven Life Sciences?
Suven Life Sciences' management team is headed by:
- Venkateswarlu Jasti - CHM
- P. Subba Rao - CFO
- Shrenik Soni - CCO
- Sudha Jasti - EDR
- M. Gopalakrishna - NID
- Syed Hasnain - NID
- Santanu Mukherjee - NID
- M. Naidu - NID
- J.A.S Padmaja - NID
- D. Prasad - NID